Testosterone for Women in Menopause: What Is Approved and Who Prescribes It

This article contains affiliate links. If you choose a provider through one of our links, RangeYourself may earn a commission at no extra cost to you. See our How We Rank page for our full methodology.

Quick Answer: If your libido has dropped off a cliff in menopause, testosterone is a real, evidence-backed option, but only for one specific problem: a formally diagnosed loss of sexual desire that's causing you distress, known as hypoactive sexual desire disorder (HSDD). No testosterone product is FDA-approved for women for any use, which means every prescription a woman receives in the US today is off-label or compounded. And because testosterone is a Schedule III controlled substance, getting it through telehealth is genuinely harder than getting estrogen or progesterone online. Below is the verified regulatory picture, what the evidence supports and doesn't, and exactly which online menopause programs prescribe it, where, and at what price, checked directly against each provider's own site.

The question underneath "would testosterone help?" is usually "is something actually wrong with me, or is this just what menopause is?" The honest answer is that a real, physical drop in desire is common in menopause, and for a specific pattern of it, testosterone has genuine trial evidence behind it. It is not a cure-all, it is not approved by the FDA, and it is not something every online menopause program can legally hand you no matter where you live. All three of those things can be true at once, and none of them means testosterone isn't worth understanding.

What's Actually FDA-Approved for Women: The Regulatory Truth

Start with what the FDA itself says. Its own testosterone information page states plainly: "Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition" (FDA, Testosterone Information, accessed September 4, 2026). The FDA doesn't phrase this as a direct "nothing is approved for women" statement; instead, it defines the approval as men-only, which has the same practical effect: there is no FDA-approved testosterone product for women, for any indication, at any dose.

That reading is confirmed from the clinical side, too. The Global Consensus Position Statement on testosterone therapy for women, endorsed by roughly ten societies including The Endocrine Society and the International Menopause Society, states it directly: "Because no approved female product is presently approved by a national regulatory body, male formulations can be judiciously used in female doses and blood testosterone concentrations must be monitored regularly" (Davis et al., Journal of Clinical Endocrinology & Metabolism, 2019). In practice, that means every testosterone prescription a woman in the US receives today is either an off-label use of a men's product at a fraction of the dose, or a compounded preparation mixed by a pharmacy rather than a finished, FDA-reviewed drug.

What the Evidence Actually Supports, and What It Doesn't

Testosterone for women in menopause has been studied more than most people assume, and the results are more specific than a blanket "it works" or "it doesn't." The Global Consensus Position Statement grades the evidence explicitly: "The only evidence-based indication for the use of testosterone in women is for the treatment of postmenopausal women who have been diagnosed as having HSDD after formal biopsychosocial assessment" (Level I evidence, Grade A recommendation).

HSDD, hypoactive sexual desire disorder, means a persistent, distressing loss of sexual desire, diagnosed against established clinical criteria rather than a general sense that libido "isn't what it used to be." The consensus statement is explicit that it's a distinct condition from arousal problems, and that a real diagnosis, not a self-assessment, is the starting point.

Just as important is what the same evidence review says testosterone does not reliably do for women. The graded findings, all from the same statement:

• Cognition: evidence is graded "insufficient" to support a benefit
• Depressed mood: Level I evidence, Grade B, no significant effect
• Bone density at 12 months: Level I evidence, Grade A, no significant effect
• Lean mass, fat mass, and muscle strength: no significant effect found

That's a meaningfully narrower claim than "testosterone helps with menopause symptoms" in general, and it's worth holding onto both directions: real evidence for HSDD specifically, and an evidence base that does not currently back the broader hopes (mood, cognition, bone, muscle) that sometimes get attached to it.

One more piece worth being precise about: The Menopause Society (formerly NAMS) does not have an official position statement on testosterone. Its current guidance lives in a 2023 Practice Pearl (Parish & Kling, Menopause, 2023), and the Pearl says so itself: "It is not an official position of The North American Menopause Society (NAMS)." The Pearl agrees that HSDD is the sole evidence-based indication, and adds a detail worth knowing: "except in Australia, where a transdermal 1% testosterone cream is available by prescription," no country has an approved testosterone product for women (a fact the Pearl traces to a 2021 ISSWSH guideline, not the 2019 global consensus statement above). It also weighs in on compounding directly: "Compounded products cannot be recommended because of lack of efficacy and safety data," while noting that off-label use of a male formulation "at approximately one-tenth of the dose for men" is a reasonable approach. That tension between compounded and off-label male-dose dosing shows up again below, because it's exactly how several online providers differ from each other.

The Timely Part: The FDA Is Holding a Workshop on Exactly This Question on September 17, 2026

Here's why this is worth reading about right now rather than someday. The FDA is holding a public workshop titled "Testosterone Use in Menopausal Women" on September 17, 2026, hybrid at White Oak (docket FDA-2026-N-5479), announced via a Federal Register notice published August 18, 2026. The public comment period stays open through October 19, 2026.

It's important to be precise about what this workshop is and isn't. In the FDA's own words: "The purpose of the workshop is to examine the current scientific evidence and critical knowledge gaps... to help inform future research and potential drug development in this area." That's evidence-gathering language, not approval language. This workshop does not mean a testosterone product for women is about to be approved, does not change any current prescribing rule, and is a separate docket from an unrelated April 2026 proceeding on the male testosterone indication (FDA-2025-N-6743). What it does signal is that the FDA is formally looking at a gap that's existed for decades. It's the reason this is a good moment to understand exactly where things stand today, not a reason to wait for something that isn't imminent.

Why Testosterone Is Hard to Get Through Telehealth

If you've noticed that your menopause program prescribes estrogen and progesterone without much friction, but goes quiet on testosterone, that's not an oversight. It's a controlled-substance problem, and several providers say so themselves.

Alloy states it plainly on its own blog: "At Alloy, our physicians currently do not prescribe testosterone since there is no FDA approved version for women, it is a Schedule III controlled substance, and requires frequent levels, all of which adds challenges for safe telehealth prescribing" (myalloy.com, accessed September 4, 2026).

Evernow, which doesn't currently prescribe it but says it's working toward doing so, gives the same reason: "Testosterone therapy, although not FDA-approved for use in women is often used for low libido as a compounded preparation. However, is difficult to prescribe through telemedicine since it is regulated as a controlled substance in many states and that we are working to be able to prescribe it in the future" (evernow.com/symptoms/low-libido, accessed September 4, 2026).

Gennev, which does not prescribe it at all, cites the same core issue among its reasons: it's a controlled substance, there's no FDA-approved female-dosed product, and it needs in-person monitoring (help.gennev.com, accessed September 4, 2026: "No, we do not prescribe testosterone.").

And MyMenopauseRx, which does prescribe it but only to patients in Illinois, states the constraint directly on its own site: "testosterone is a controlled substance in the United States and your specialist is unable to prescribe controlled substances via virtual care" (mymenopauserx.com/faq, accessed September 4, 2026).

Four different companies, in their own words, pointing at the same regulatory wall. That's why "does my menopause program prescribe testosterone" is really a state-by-state question, not a yes-or-no one, and why the table below records exactly where each provider stands rather than a single verdict.

Who Actually Prescribes Testosterone to Women Online, Verified Provider by Provider

RangeYourself checked 11 online menopause and hormone-therapy providers directly against each provider's own current site. Here's where each one stands, as of September 4, 2026.

Two of these rows deserve more context than a table cell allows.

Midi's compounded testosterone, and the unresolved tension with it

Midi's dedicated testosterone page states: "Midi's clinicians are working to fill that gap through evidence-informed, compounded testosterone therapy," and describes its approach as "safe, low-dose therapy that can be paused or changed anytime" (joinmidi.com/testosterone). That's worth holding next to the Menopause Society's 2023 Practice Pearl, quoted above, which says "Compounded products cannot be recommended because of lack of efficacy and safety data" while stating that "it is reasonable to prescribe off-label an approved formulation for men at approximately one-tenth of the dose for men." Midi's own page describes its product as compounded, not as an off-label male formulation. RangeYourself isn't in a position to resolve that gap for you. Both facts are accurate and attributed to their own sources, and it's a real question worth raising with any prescriber before starting a compounded product.

Joi's rebrand and its own published prices

Joi has rebranded: choosejoi.co now redirects to joiandblokes.com (Joi + Blokes). Its women's hormone-health product page lists testosterone as a selectable form with its own published prices: "Injection $59/mo, Cream $69/mo" (joiandblokes.com, accessed September 4, 2026, figures as published by Joi + Blokes). It's the only provider on this list with a public per-form testosterone price. Its state exclusion list, reproduced in the table above, is also its own.

If Your Program Doesn't Prescribe Testosterone

Most of the largest online menopause programs don't currently prescribe testosterone, and that's not a red flag on their part. It's the same controlled-substance reality described above. If testosterone isn't available to you where you live, or your program is one of the "no" rows above, there are still real, verified paths forward.

Winona prescribes DHEA instead. Asked directly whether it prescribes testosterone, Winona's own FAQ answers: "No, Winona does not prescribe testosterone. There's currently no FDA-approved testosterone therapy for women for the treatment of menopausal symptoms. However, we do prescribe DHEA (dehydroepiandrosterone), a hormone precursor that can help gently raise your testosterone levels and provide similar benefits" (bywinona.com/faq). Winona's own pricing across its HRT lineup: Progesterone Capsules from $39/mo; Estrogen Tablets from $54/mo; Vaginal Estrogen Cream from $89/mo; Estrogen Body Cream from $89/mo; Progesterone Body Cream from $89/mo; Estrogen+Progesterone Combo Cream from $89/mo; Estrogen Patch from $149/mo; DHEA from $27/3-mo supply. (All phrased 'From $X per month', starting prices that may rise with dose/formulation.) See our Winona pricing for current details.

Gala doesn't offer a testosterone product either. Gala's own hormone-health page lists only estradiol (pill or patch), progesterone (oral or vaginal), and vaginal estradiol among its medications, with no testosterone product found anywhere on its site (verified 2026-07-27). Gala's flat monthly program price: $69/month, 'all included, no insurance needed' (covers medication, provider review, and ongoing care) Check current details at Gala.

If your goal is broader menopause symptom relief rather than testosterone specifically, two more covered programs are worth a look: Sesame, whose menopause subscription runs Menopause subscription 'From $59/month' (hero: '$59/mo.'); medication costs are not included in the subscription price and vary, and WeightWatchers Med+ Meno, priced at WW Med+ Meno (HRT-prescribing tier): $88/month ongoing. WW Core+ Meno (non-prescribing, NO-HRT tier): 'STARTING AT $22/MONTH' (verbatim 'starting at' figure, billing basis, plain monthly vs prepaid-commitment effective rate, NOT confirmed; see unverifiedFlags; this tier does not prescribe HRT, so it is secondary for this registry). 'GLP-1 and HRT cost not included' in membership (medications may be subject to insurance). First-month/intro pricing is in introPromoPrice. (Med+ Meno 'YOUR FIRST MONTH $65' then $88/month (intro/first-month framing); Core+ Meno has no separate intro price, see recurringPrice ('STARTING AT $22/MONTH')). Neither's testosterone-prescribing status was part of this verification pass, so we're not making a claim about it either way here. These are general menopause-care mentions, not testosterone recommendations.

How We Verified This

Every regulatory and provider claim on this page was checked directly against a primary source between September 3 and September 4, 2026: the FDA's own testosterone information page, the peer-reviewed Global Consensus Position Statement, The Menopause Society's 2023 Practice Pearl, the Federal Register notice for the FDA's September 17 workshop, and each provider's own current site (FAQ pages, product pages, or first-person blog statements). Where a provider's testosterone status wasn't stated anywhere on its own pages, we recorded that as "not stated," never as "doesn't offer." No provider fact on this page comes from a third-party aggregator, an affiliate network listing, or an outdated cache. Read our full approach at How We Rank.

FAQ

My libido is gone in menopause. Would testosterone help?

For a specific pattern, a persistent, distressing loss of sexual desire that meets the clinical criteria for HSDD, yes, testosterone has real trial evidence behind it (Level I, Grade A, per the Global Consensus Position Statement). It's not a general fix for "libido isn't what it used to be," and getting it usually starts with a formal evaluation, not a self-diagnosis.

Is testosterone FDA-approved for women?

No. The FDA states testosterone products are approved only for men with low testosterone and an associated medical condition. There is no FDA-approved testosterone product for women for any use, which is why every prescription a woman receives is off-label or compounded.

What is HSDD?

Hypoactive sexual desire disorder: a persistent, distressing loss of sexual desire, diagnosed against established clinical criteria after a formal evaluation. It's the only indication the Global Consensus Position Statement grades as evidence-based for testosterone in women.

Why is it so hard to get a testosterone prescription through telehealth?

Testosterone is a Schedule III controlled substance, and several providers, including Alloy, Evernow, and MyMenopauseRx, say directly on their own sites that controlled-substance rules make virtual prescribing harder than it is for non-controlled hormones like estrogen or progesterone. Some states also restrict it outright for certain providers.

Is compounded testosterone safe for women?

The evidence is unsettled, and providers are split. The Menopause Society's 2023 Practice Pearl states that "Compounded products cannot be recommended because of lack of efficacy and safety data," while Midi, one of the larger online menopause providers, prescribes a compounded testosterone product on the basis that it fills a gap in FDA-approved options. Both facts are accurately attributed to their sources; RangeYourself isn't resolving that disagreement for you.

Does the FDA's September 2026 workshop mean a testosterone product for women is about to be approved?

No. The FDA describes the September 17, 2026 workshop's purpose as examining "the current scientific evidence and critical knowledge gaps... to help inform future research and potential drug development," which is evidence-gathering language, not an approval signal. No prescribing rule changes as a result of the workshop itself.

Which online programs actually prescribe testosterone to women, and where?

Of the 11 providers RangeYourself verified, six currently prescribe it in some form: Midi (compounded, states-limited), Hone Health, Defy Medical, MyMenopauseRx (Illinois only), Elektra Health (New York only), and Joi + Blokes (with a named list of excluded states). Four explicitly do not: Winona (prescribes DHEA instead), Alloy, Evernow (working toward it), and Gennev. Wisp doesn't state a position on its menopause pages. See the full table above for sources.

What can I use if my program doesn't prescribe testosterone?

Winona prescribes DHEA, a hormone precursor, as its alternative, describing it as able to "gently raise your testosterone levels and provide similar benefits." If your main concern is broader menopause symptom relief rather than testosterone specifically, programs like Gala, Sesame, and WeightWatchers Med+ Meno are worth comparing on price and coverage.

Medical Disclaimer

RangeYourself provides educational information, not medical advice. Testosterone is a Schedule III controlled substance and no product is FDA-approved for use in women; any prescription is off-label or compounded and requires individualized evaluation by a licensed clinician. This content does not recommend, endorse, or advise for or against any specific treatment. Consult a healthcare provider before starting any medication.

Sources

• U.S. Food and Drug Administration, Testosterone Information, accessed September 4, 2026.
• Davis SR, Baber R, Panay N, et al., "Global Consensus Position Statement on the Use of Testosterone Therapy for Women," Journal of Clinical Endocrinology & Metabolism 104(10):4660-4666, 2019.
• Parish SJ, Kling JM, "Testosterone use for hypoactive sexual desire disorder in postmenopausal women," Practice Pearl, Menopause 30(7):781-783, 2023 (not an official position of The Menopause Society).
• U.S. Food and Drug Administration, public workshop "Testosterone Use in Menopausal Women," docket FDA-2026-N-5479, Federal Register notice published August 18, 2026, comment period through October 19, 2026.
• Midi Health, joinmidi.com/testosterone, accessed September 4, 2026.
• Winona, bywinona.com/faq, accessed September 4, 2026.
• Hone Health, honehealth.com/womens/testosterone-cream/, accessed September 4, 2026.
• Alloy, myalloy.com (blog), accessed September 4, 2026.
• Evernow, evernow.com/symptoms/low-libido, accessed September 4, 2026.
• Defy Medical, defymedical.com/blog/do-women-have-testosterone, accessed September 4, 2026.
• MyMenopauseRx, mymenopauserx.com/faq, accessed September 4, 2026.
• Elektra Health, elektrahealth.com FAQ, accessed September 4, 2026 (site blocks automated readers; content confirmed via read-only proxy of the same URL).
• Gennev, help.gennev.com/article/18, accessed September 4, 2026.
• Joi + Blokes, joiandblokes.com/shop/women/hormone-health/hrt/, accessed September 4, 2026.
• Wisp, hellowisp.com, accessed September 4, 2026.
• Gala, galaglp1.com/hormone-health, verified 2026-07-27 (RangeYourself registry).

Related Reading

• Menopause Treatment: Best Online Programs (2026)
• Best Online HRT for Perimenopause and Menopause (2026 Guide)
• Should I Start HRT Before Starting a GLP-1?